Kenneth P. H. Pritzker

Senior Advisor @Rna Diagnostics Inc

CEO, March 2010- March 2016 Rna Diagnostics is a Canadian cancer diagnostics company developing diagnostic tools to improve chemotherapy management. The company’s first product, RNA Disruption Assay™ (RDA™), determines early in a woman’s breast cancer treatment whether she is responding to the chemotherapy. If the chemotherapy is not working effectively she can be switched quickly to other treatment, avoiding the harmful side-effects of ineffective chemotherapy and thereby improving her outcome. For more information on Rna Diagnostics, please visit 1st prize winner: RESI Innovation Challenge, September 2015 TieQuest Business Competition, April 2011 Sanofi Pasteur Biotechnology Venture Challenge November 2010